Interestingly and perhaps not surprisingly, in the early clinical testing of vismodegib [15], a medulloblastoma patient who presented with widespread metastatic disease and had a PTCH1 mutation responded rapidly and achieved dramatic tumor regression. Here, PTCH1 is linked to medulloblastoma.